Choose Your Country or Region

LY294002

Name: LY294002
Brand: Selleck Chemicals
SKU: S1105
Rating: 5 (1409 reviews)

Catalog No.S1105 Synonyms: SF 1101, NSC 697286

For research use only.

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.

CAS No. 154447-36-6

Selleck's LY294002 has been cited by 1409 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Related Compound Libraries

Other PI3K Products

Taselisib (GDC 0032)^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.
Pilaralisib (XL147)^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin (KY 12420)

Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Download Inhibitor Catalog

PI3K Signaling Pathway Map

Biological Activity

Description

Targets

CK2 ^[5] (Cell-free assay)	p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	DNA-PK ^[6] (Cell-free)
98 nM	0.5 μM	0.57 μM	0.97 μM	1.4 μM

In vitro

LY294002 is not exclusively selective for the PI3Ks, and could in fact act on other lipid kinases and additional apparently unrelated proteins. LY294002 is shown to inhibit not only mTOR and DNA-PK, but also other protein kinases, such as CK2 (casein kinase 2) and Pim-1^[5]. LY294002 inactivates Akt/PKB, consequently inhibiting cell proliferation and inducing apoptosis. LY294002 demonstrates a remarkable growth-inhibitory and apoptosis-inducing effect in these colon cancer cell lines, with decreased expression of phosphorylated Akt (Ser473). ^[2]LY294002 induces marked nuclear pyknosis and diminished cytoplasmic volume in the tumor cells. Thus, LY294002 markedly inhibits ovarian cancer cell proliferation in vitro. LY294002 induces specific G1 arrest in cell growth, leading to almost complete inhibition of melanoma cell proliferation and partial inhibition of MG-63 (osteosarcoma cell line) proliferation. The effect of LY294002 on cell cycle progression may provide insights into a possible link between the PI3K activation pathway and cancer cell cycle regulation. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Sf9 cells	NHK1U5FHfW6ldHnvckBie3OjeR?=			MVLJcohq[mm2aX;uJI9nKEircz30ZYdo\WRiYn;2bY5mKFCLM1ug[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyxiSVO1NF0yOCEQvF2u	NVnsVHYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC5PVg{PTFpPkGwPVk5OzVzPD;hQi=>
HeLa cells	NYHBNJdySmmwZHnu[{Bi\m[rbnn0fUBie3OjeR?=			M4[5c2JqdmSrbnegZYZncW6rdImg[o9zKFCLMz3rbY5ie2ViaYPvcIF1\WRiZoLvcUBJ\UyjIHPlcIx{NCCNaU22JO69VQ>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTZ3OEi3NEc,OTV4NUi4O\|A9N2F-
HeLa cells	Mn3RSpVv[3Srb36gZZN{[Xl?			MmHoTY5pcWKrdHnvckBw\iCvVF;SJJBzd3SnaX6gbZNwdGG2ZXSg[pJwdSCKZVzhJINmdGy\|LDDJR\|UxRTJwNTFOwG0v	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTZ3OEi3NEc,OTV4NUi4O\|A9N2F-
HeLa (human carcinoma) cells.	MVHGeY5kfGmxbjDhd5NigQ>?			Mo[5TY4hfmm2cn:gbY5pcWKrdHnvckBw\iCGTlGt[IVx\W6mZX70JJBzd3SnaX6gb4lv[XOnKFTORU1RUyliZoLvcUBJ\UyjIDjoeY1idiClYYLjbY5wdWFrIHPlcIx{NCCLQ{WwQVEvPCEQvF2u	M3T1R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkW4PFcxLz5zNU[1PFg4ODxxYU6=
human PC3 cells	MX3Qdo9tcW[ncnH0bY9vKGG\|c3H5	MWeyOUDPxE1?	MWWxNlAhcA>?	Mm\kRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{OgZ4VtdHNiYYSgNlUhfU1iYX\0[ZIhOTJyIHjyd{BjgSCPVGSgZZN{[XlicnXsZZRqfmVidH:gSG1UVw>?	NUC4NZRTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[2PFAyPTlpPkG2OlgxOTV7PD;hQi=>
human BJ cells	NWjiSGNNTnWwY4Tpc44h[XO\|YYm=	NHHBTJczPSEQvF2=	MlfWNkBp	MnPLRYN1cX[jdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHH0JHRpejNyODDpckBRTEeILYP0bY12dGG2ZXSgd4VzfW1ic4ThdpZm\CCqdX3hckBDUiClZXzsd{BifCB{NTD1UUB1emWjdHXkJFIhcHK\|IHLl[o9z\SCSRFfGJINp[WyuZX7n[UBjgSCrbX31co9jdG:2dHnu[y=>	M{fYfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{[3NFg2Lz5zNke2O\|A5PTxxYU6=
human BJ cells	MVLGeY5kfGmxbjDhd5NigQ>?	MUWyOUDPxE1?	NFLoUIMzKGh?	MUXJcohq[mm2aX;uJI9nKFCLM1ugd4lodmGuaX7nJIlvKFCGR1[td5RqdXWuYYTl[EB{\XK3bTDzeIFzfmWmIHj1cYFvKEKMIHPlcIx{KHS{YX7z[oVkfGWmIIfpeIgheGyjc33p[EBGT0[SL2DIJIRwdWGrbjDv[kBCc3RiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiUFitSWdHWCC{ZXTpd5RzcWK3dHnvckB1dyCybHHzcYEhdWWvYoLhcoUh[XRiMkWgeW0hfHKnYYTl[EAzKGi{czDi[YZwemViUFTHSkBkcGGubHXu[4Uh[nliY3;u[o9k[WxibXnjdo9{[2:yeR?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd4N{C4OUc,OTZ5NkewPFU9N2F-
mouse mast cells	NW\ib25NTnWwY4Tpc44h[XO\|YYm=	MXOyNEDPxE1?		NWPqWGtSUW6qaXLpeIlwdiCxZjDTR2YucW6mdXPl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBud3W\|ZTDtZZN1KGOnbHzzJIF1KDJyIN88US=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd6OUe0Nkc,OTZ5OEm3OFI9N2F-
THP1 cells	MYLGeY5kfGmxbjDhd5NigQ>?			NEDydmVKdmirYnn0bY9vKG:oIF3DVFEucW6mdXPl[EBkcGWvb4ThfIl{KG:oIGTIVFEh[2WubIOsJGlEPTB;M{eg{txONg>?	NY\TcJdLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3PFk4PDJpPkG2O\|g6PzR{PD;hQi=>
mouse Raw264 macrophage	MmXDSpVv[3Srb36gZZN{[Xl?			MYjJcohq[mm2aX;uJI9nKEN3YT3t[YRq[XSnZDDQT2IwSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDtc5V{\SCUYYeyOlQhdWGlcn;wbIFo\SxiSVO1NF0yOCEQvF2u	MoHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ5OEm3OFIoRjF4N{i5O\|QzRC:jPh?=
THP1 cells	M4nQdmZ2dmO2aX;uJIF{e2G7			NITJXplKdmirYnn0bY9vKG:oIF3DVFEucW6mdXPl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBVUFBzIHPlcIx{NCCLQ{WwQVEvPjVizszNMi=>	NWTCVWNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3PFk4PDJpPkG2O\|g6PzR{PD;hQi=>
THP1 cells	MnXQSpVv[3Srb36gZZN{[Xl?			MkCxTY5pcWKrdHnvckBw\iCVQ1[xMYlv\HWlZXSgVGtDN0GtdDDwbI9{eGixconsZZRqd25iaX6gWGhROSClZXzsd{whUUN3ME2xMlAyKM7:TT6=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd6OUe0Nkc,OTZ5OEm3OFI9N2F-
human A375 cells	NVTrbIpPWHKxbHnm[ZJifGmxbjDhd5NigQ>?		NUL1e\|hiPDZiaB?=	NHfXO3NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGzO\|Uh[2WubIOgZYZ1\XJiNE[gbJJ{NCCLQ{WwQVgvPCEQvF2u	MnPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdyNEmyOFgoRjF5MES5NlQ5RC:jPh?=
HeLa cells	MW\GeY5kfGmxbjDhd5NigQ>?			MljjTY5pcWKrdHnvckBw\iCDWD23OVA{KGKrbnTpcochfG9icnXjc41jcW6jboSgVIxsOyCneIDy[ZN{\WRiaX6gTIVN[SClZXzsd{BjgSCZZYP0[ZJvKGKub4SsJGlEPT1\|IN88UU4>	NXHIfI1kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexN\|UzPDhpPkG3NVM2OjR6PD;hQi=>
human SW480 cells	M4n4RmZ2dmO2aX;uJIF{e2G7	MYGyNEDPxE1?	NV3obnMyOjRiaB?=	NF;3VmVF\WO{ZXHz[UBqdiC\|dYL2bZZqdiCneIDy[ZN{cW:wIHnuJIh2dWGwIGPXOFgxKGOnbHzzJIF1KDJyIIXNJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0JIFv[Wy7c3nz	NFXIUI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S3Nlk3Oid-MUe0O\|I6PjJ:L3G+
human A375 cells	Mo\5VJJwdGmoZYLheIlwdiCjc4PhfS=>			Ml;qTY5pcWKrdHnvckBw\iC\|ZYL1cU1qdmS3Y3XkJJBzd2yrZnXyZZRqd25ib3[gbJVu[W5iQUO3OUBk\WyuczygTWM2OD16LkSg{txONg>?	M3znXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkCxO\|M6Lz5zN{[wNVc{QTxxYU6=
human A2780 cells	NHm1N4JCeG:ydH;zbZMh[XO\|YYm=	NV;0TXRQOiEQvF2=	MUCxNkBp	MX\JcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHPpd5Bt[XSrbj3y[ZNqe3SjboSgbJVu[W5iQUK3PFAh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSWu2IHzleoVtKGG2IEKgeW0h[W[2ZYKgNVIhcHK\|IHL5JIludXWwb3Lsc5Qh[W6jbInzbZMv	NIe5WIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[4OFAyQCd-MUe2PFQxOTh:L3G+
human H4 cells	M1:4[mZ2dmO2aX;uJIF{e2G7		MX6yJIg>	MYnE[YNz\WG\|ZTDpckBHYV[HLWLGVEshfmW\|aXPs[UBqdnSnboPpeJkheGW{IHPlcIwhcW5iaIXtZY4hUDRiY3XscJMh[W[2ZYKgNkBpenNicnXsZZRqfmVidH:gZ49vfHKxbB?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDB{NEW4OEc,OThyMkS1PFQ9N2F-
Sf9 cells	MXXGeY5kfGmxbjDhd5NigQ>?			NVK4[JRpUW6qaXLpeIlwdiCxZjDDT\|Ih\XiycnXzd4VlKGmwIGPmPUBk\WyuczygTWM2OD14Lkmg{txONg>?	M{jadFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{KxO\|E3Lz5zOEOyNVcyPjxxYU6=
rat RBL2H3 cells	M2fodWZ2dmO2aX;uJIF{e2G7			NHm1fFNKdmirYnn0bY9vKG:oIFGyN\|E5Py2rbnT1Z4VlKGSnZ4LhcpVt[XSrb36gbY4hemG2IGLCUFJJOyClZXzsdy=>	M4f6XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{K4O\|E3Lz5zOEOyPFcyPjxxYU6=
human U87MG cells	MVLGeY5kfGmxbjDhd5NigQ>?			MoDiTY5pcWKrdHnvckBw\iCJU1uzMYJmfGFiaX6gbJVu[W5iVUi3UWch[2WubIOgZpkhTUyLU1GsJGlEPTB;OD6xJO69VS5?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN2NU[wPUc,OTh\|NEW2NFk9N2F-
human H460 cells	MV;GeY5kfGmxbjDhd5NigQ>?	Mn3IN\|Ah\|ryP		NX7UXIt6UW6qaXLpeIlwdiCxZjDQTVNMKGmwIHj1cYFvKEh2NkCgZ4VtdHNiYYPz[ZN{\WRiYYOgRYt1KHCqb4PwbI9zgWyjdHnvckBifCCVZYKgOFc{KHWyIITvJFMxKHWP	NYmzOFlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1NFE3ODFpPkG4OVAyPjBzPD;hQi=>
human U251HRE cells	M{TFOGZ2dmO2aX;uJIF{e2G7			MmfVTY5pcWKrdHnvckBw\iCqeYDvfIliNWmwZIXj[YQhUEmIMTDhZ5RqfmG2aX;uJIlvKGi3bXHuJHUzPTGKUlWgZ4VtdHNiYomgZ4VtdCCkYYPl[EBz\XCxcoTldkBo\W6nIHHzd4F6	M1nZZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUCxOlAyLz5zOEWwNVYxOTxxYU6=
human 184B5 cells	M3;2XGN6fG:2b4jpZ:Kh[XO\|YYm=			NUDXb2tUS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hOTh2QkWgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyPUO5MlM4KM7:TT6=	M4nyOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
human MDA-MB-468 cells	MlOzR5l1d3SxeHnjxsBie3OjeR?=			MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy\|IHL5JHNTSiCjc4PhfUwhUUN3ME2xNE41KM7:TT6=	Mli0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
human MDA-MB-468 cells	MnGxR5l1d3SxeHnjxsBie3OjeR?=			MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy\|IHnuJJBz\XOnbnPlJI9nKDFyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3OjeTygS2k2OD16LkKg{txONg>?	M3XqcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
MDA-MB-231 cells	MnTGR5l1d3SxeHnjxsBie3OjeR?=			NX:1bI56S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:Pi55MTFOwG0v	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
human MDA-MB-468 cells	MXjDfZRwfG:6aXRCpIF{e2G7			NX7hZ4VnS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{BqdiCycnXz[Y5k\SCxZjCyNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZnwxIxiSVO1NF01Njd4IN88UU4>	NWDqTWE5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MDA-MB-231 cells	M4XubGN6fG:2b4jpZ:Kh[XO\|YYm=			MoXER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDpckBxemW\|ZX7j[UBw\iBzMDD1UUBkcGyxcn;xeYlv\SCkeTDTVmIh[XO\|YYmsJGdKPTB;ND6zOUDPxE1w	MnLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
human MDA-MB-231 cells	MVjDfZRwfG:6aXRCpIF{e2G7			MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHnuJJBz\XOnbnPlJI9nKDJyIN88UUBkcGyxcn;xeYlv\SCkeTDTVmIh[XO\|YYmsJGdKRTNwM{Kg{txONg>?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
human MCF7 cells	NFXTR2dEgXSxdH;4bYPDqGG\|c3H5			MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m9N{4yPiEQvF2u	NVK4TVByRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MCF7 cells	MYrDfZRwfG:6aXRCpIF{e2G7			MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEGwJJVOKGOqbH;yc5F2cW6nIHL5JHNTSiCjc4PhfUwhT0l3ME2zMlA5KM7:TT6=	NUjQcIJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MCF7 cells	NH3M[4xEgXSxdH;4bYPDqGG\|c3H5			MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEKwJO69VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLNUC9Nk43OyEQvF2u	NE[1dlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
Sf21 cells	MWfGeY5kfGmxbjDhd5NigQ>?			MkOwTY5pcWKrdHnvckBw\iCvb4Xz[UBz\WOxbXLpcoFvfCCSSUPLZYxxcGFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{NWmwZnXjeIVlKFOoMkGgZ4VtdHNuIFnDOVA:OC53IN88UU4>	NFGyVHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0PFI3QSd-MUm3OFgzPjl:L3G+
Sf9 cells	NXHpe4xG\my3b4Lld4NmdnRicH;sZZJqgmG2aX;uJIF{e2G7			NIfn[VdKdmirYnn0bY9vKG:oIHj1cYFvKFCLM1vnZY1u[SCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIJ6KG[udX;y[ZNk\W62IIDvcIFzcXqjdHnvckBie3OjeR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF{MU[zNUc,OjFzMkG2N\|E9N2F-
Sf9 cells	MVvGcJVwemW\|Y3XueEBxd2yjcnn6ZZRqd25iYYPzZZk>			NVHoS4RSUW6qaXLpeIlwdiCxZjDoeY1idiCSSUPLZYxxcGFiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{BjgSCobIXvdoV{[2WwdDDwc4xiemm8YYTpc44h[XO\|YYmsJGlEPTB;MD61OUDPxE1w	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF{MU[zNUc,OjFzMkG2N\|E9N2F-
human IGROV1 cells	M2GxdGZ2dmO2aX;uJIF{e2G7		MVSyOEBp	M2Gxc2NmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGlIWk:YMTDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{GgdIhie2ViYYSgOUBnd2ymIFnDOVAh[W[2ZYKgNlQhcHK\|IHL5JIZtd3diY4n0c41mfHK7	M4TS[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkG2NVUyLz5{MUKxOlE2OTxxYU6=
human IGROV1 cells	MkXmSpVv[3Srb36gZZN{[Xl?		NIfibpAzPCCq	MmG0R4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gTWdTV1ZzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCJMTDwbIF{\SCjdDCxJIZwdGRiSVO1NEBi\nSncjCyOEBpenNiYomg[oxwfyCleYTvcYV1enl?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJzNkG1NUc,OjF{MU[xOVE9N2F-
human IGROV1 cells	MX;GeY5kfGmxbjDhd5NigQ>?		M2[3U\|I1NzR6IHi=	MX3Jcohq[mm2aX;uJI9nKFCLM1uvRYt1KGmwIHj1cYFvKEmJUl;WNUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCleXPsbY4hTDFibHX2[Ywh[XRiMTD0c{A2KHSrbXXzJGlEPTBiYX\0[ZIhOjRidH:gOFghcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	NUTicYpqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyNVYyPTFpPkKxNlE3OTVzPD;hQi=>
human IGROV1 cells	MXrGeY5kfGmxbjDhd5NigQ>?		Mo[yNlQwPDhiaB?=	MnTOTY5pcWKrdHnvckBw\iCSSUPLM2FsfCCrbjDoeY1idiCLR2LPWlEh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSUuWIHzleoVtKGG2IEGgeI8hPSC2aX3ld{BKSzVyIHHmeIVzKDJ2IITvJFQ5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	MlL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MU[xOVEoRjJzMkG2NVUyRC:jPh?=
human HCT116 cells	MUfDfZRwfG:6aXRCpIF{e2G7		NF\yfWE4OiCq	NWi3fVJ4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PTZwMEGg{txONg>?	NWL0UZVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OFUzPTBpPkKxPVQ2OjVyPD;hQi=>
human KB cells	MYnDfZRwfG:6aXRCpIF{e2G7		M{\RTVczKGh?	NWP2OGs1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0JiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME20OE44PiEQvF2u	M4TzfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUS1NlUxLz5{MUm0OVI2ODxxYU6=
HUVEC	NIfVOYZHfW6ldHnvckBie3OjeR?=	NWXVWWJCOTBvMkWg{txO	MnLqN\|AhdWmw	MmjqTY5pcWKrdHnvckBw\iCWTl\hcJBp[S2\|dHnteYxifGWmIHj1cYFvKEmFQV2tNUBxem:vb4TldkBi[3Srdnn0fUBmgHC{ZYPz[YQhcW5iSGXWSWMh[XO\|ZYPz[YQh[XNiYnX0ZU1o[WyjY4Tvd4ll[XOnIHHjeIl3cXS7IHH0JFExKHSxIEK1JJVOKHC{ZYTy[YF1\WRiZn;yJFMxKG2rboOgZoVnd3KnIGTOSoFteGijIHPoZYxt\W6pZTDt[YF{fXKnZDDh[pRmeiB3IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYm=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB{NkSxNEc,OjJyMk[0NVA9N2F-
HUVEC	NHHWWmNHfW6ldHnvckBie3OjeR?=	NX70dmtmOTBvMkWg{txO	MVSxOkBp	M3LFWWlvcGmkaYTpc44hd2ZiVF7GZYxxcGFvc4TpcZVt[XSnZDDJR2FONTFibWLORUBmgHC{ZYPzbY9vKGmwIFjVWmVEKGG2IEGwJJRwKDJ3IIXNJJBz\XS{ZXH0[YQh\m:{IEG2JIhzeyCkZX\vdoUhXE6IYXzwbIEh[2ijbHzlcodmKG2nYYP1doVlKGGodHXyJFYhcHK\|IHL5JHJVNVCFUjDhcoFtgXOrcx?=	NX;0cYs{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwNlY1OTBpPkKyNFI3PDFyPD;hQi=>
human HCT116 cells	M4LDcmZ2dmO2aX;uJIF{e2G7	NUDi[IlPOTBizszN		MXzJcohq[mm2aX;uJI9nKEGtdDDlfJBz\XO\|aX;uJIlvKGi3bXHuJGhEXDFzNjDj[YxteyCjdDCxNEB2VSCkeTDpcY12dm:kbH;0JIFv[Wy7c3nz	MknTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUK3NlEoRjJ{MkGyO\|IyRC:jPh?=
human HCT116 cells	NF\o[pJHfW6ldHnvckBie3OjeR?=	MmHYNVAh\|ryP		M4r6e2lvcGmkaYTpc44hd2ZiUFmzT4FteGijIFixNFQ4WiCvdYThcpQhcW5iaIXtZY4hUEOWMUG2JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiQXv0JHNmejR5MzDwbI9{eGixconsZZRqd25iYYSgNVAhfU1iYomgbY1ufW6xYnzveEBidmGueYPpdy=>	MoHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUK3NlEoRjJ{MkGyO\|IyRC:jPh?=
human HCT116 cells	MUHGeY5kfGmxbjDhd5NigQ>?	MV6xNEDPxE1?		MVLJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDheEAyOCC3TTDifUBqdW23bn;icI91KGGwYXz5d4l{	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human HCT116 cells	NIPaSGhHfW6ldHnvckBie3OjeR?=	MnO4NVAh\|ryP	Mom0NVAhdWmw	NX;XNGJCUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgTFExPDeUIH31eIFvfCCrbjDoeY1idiCKQ2SxNVYh[2WubIOgeZNqdmdiW{OyVH1CXFBiYYSgNVAhfU1iYX\0[ZIhOTBibXnudy=>	NEXTOVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNlczOSd-MkKyNVI4OjF:L3G+
human HCT116 cells	NEfKemFHfW6ldHnvckBie3OjeR?=	M170bFExKM7:TR?=	NX31SJBSOTBibXnu	NELnXHNKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDpckBpfW2jbjDIR3QyOTZiY3XscJMhfXOrbnegX\|MzWF2DVGCgZZQhOTBidV2gZYZ1\XJiMUCgcYlvew>?	NEHkTlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNlczOSd-MkKyNVI4OjF:L3G+
human HCT116 cells	MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYm0PEBp	MUPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMhd3[ncnX4dJJme3OrbnegVGk{U2GucHjhJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;Nj63JO69VS5?	M{nyd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO\|IyLz5{MkKxNlczOTxxYU6=
human HCT116 cells	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NWC1PIppPDhiaB?=	M1TqZmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVUvQCEQvF2u	NGTIUZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNlczOSd-MkKyNVI4OjF:L3G+
human HCT116 cells	Ml;2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1nQZ\|Q5KGh?	NXPI[nhxT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUG2JINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKFCLM1vhcJBp[SCKMUC0O3IhdXW2YX70JIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;NT6zJO69VQ>?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human A549 cells	NHPMZVVEgXSxdH;4bYPDqGG\|c3H5		MlPRO\|IhcA>?	Mlf2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5	M4XpZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEiwPFUyLz5{MkS4NFg2OTxxYU6=
human PC3 cells	MX\DfZRwfG:6aXRCpIF{e2G7		M1mwdVczKGh?	NWftWXZ2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN\|IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9OlEvOzVizszNMi=>	NX\m[ZdORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PFA5PTFpPkKyOFgxQDVzPD;hQi=>
human HL60 cells	MULDfZRwfG:6aXRCpIF{e2G7		M{jLTFczKGh?	M3TR[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME25Mlk1KM7:TT6=	Mny2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OEC4OVEoRjJ{NEiwPFUyRC:jPh?=
Sf21 cells	MVHGeY5kfGmxbjDhd5NigQ>?			M1:3bGlvcGmkaYTpc44hd2ZibX;1d4Uhf2muZDD0fZBmKFCLM1vhcJBp[SCneIDy[ZN{\WRiaX6gV4YzOSClZXzsd{Bkdy2neIDy[ZN{cW6pIF6teIVzdWmwYXygTIl{NXSjZ3fl[EBpfW2jbjDwPFViKHW\|aX7nJGwu[WyyaHGtdIhwe3CqYYTp[JltcW6xc3n0c4whe3Wkc4TyZZRmKGK7IGTMR{Bj[XOnZDDwbI9{eGixcjDpcYFocW6pLDDJR\|UxRTBwNTFOwG0>	NFvuW2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWyNFY{OCd-MkK1NlA3OzB:L3G+
HEK293 cells	MY\GeY5kfGmxbjDhd5NigQ>?		NV:yTZVjOS53IHi=	MkTNSIl{eGyjY3Xt[Y51KG:oIGuzTH1NW0RiZoLvcUBpfW2jbjC1THQ3KHKnY3XweI9zKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNU42KGi{czDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\w>?	M3\z[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUO3NVU{Lz5{MkWzO\|E2OzxxYU6=
human H1299 cells	M1rpeGZ2dmO2aX;uJIF{e2G7	NESxOYcxNjFvM{Cg{txO	MUmyOEBp	NFHmcIJKdmS3Y4Tpc44hd2ZiSl7LMY1m\GmjdHXkJGNJV1BiZYjwdoV{e2mxbjDpckBpfW2jbjDINVI6QSClZXzsd{BifCByLkGgeI8hOzBidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	MnrxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4MkKwOlkoRjJ{NkKyNFY6RC:jPh?=
human H1299 cells	M3jZSGZ2dmO2aX;uJIF{e2G7	MVWwMlEuOzBizszN	M3jaWVI1KGh?	M3voVGlv\HWldHnvckBw\iCGUkWg[ZhxemW\|c3nvckBqdiCqdX3hckBJOTJ7OTDj[YxteyCjdDCwMlEhfG9iM{CgeW0h[W[2ZYKgNlQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	NX31XXVmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2NlIxPjlpPkKyOlIzODZ7PD;hQi=>
human H1299 cells	MUXGeY5kfGmxbjDhd5NigQ>?	NVfkdFh5OC5zLUOwJO69VQ>?	Mn7xNlQhcA>?	MYTEc5dvKHKnZ4XsZZRqd25ib3[gZ2lCWDJiZYjwdoV{e2mxbjDpckBpfW2jbjDINVI6QSClZXzsd{BifCByLkGgeI8hOzBidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpd{BqdiCycnXz[Y5k\SCxZjCxNFAhfWdxbXygWHJCUUxiYX7kJHBKO0tiaX7obYJqfG:{IFzZNlk1ODB{	NXv6dVh5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2NlIxPjlpPkKyOlIzODZ7PD;hQi=>
human H1299 cells	NFfCeHVHfW6ldHnvckBie3OjeR?=	NFfHeYUxNjFvM{Cg{txO	M2XBSVI1KGh?	MXHEc5dvKHKnZ4XsZZRqd25ib3[gZ2lCWDJiZYjwdoV{e2mxbjDpckBpfW2jbjDINVI6QSClZXzsd{BifCByLkGgeI8hOzBidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	NXfLRXYyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2NlIxPjlpPkKyOlIzODZ7PD;hQi=>
MDA-MB-231 cells	Mmm3R4VtdCCrbo\hd4lwdiCjc4PhfS=>		M{XzXVI1KGh?	NXnuc\|VmUW6qaXLpeIlwdiCxZjDldIl1cGWuaXHsJIdzd3e2aDDmZYN1d3JvaX7keYNm\CClZXzsJI1q\3KjdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJJBz\S2rbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBk\WyuIHnueoF{cW:wIHHzd4F6NCCLQ{WwQVAvOzhizszNMi=>	NFr3enA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiwOFExQCd-MkK4NFQyODh:L3G+
human LNCAP cells	NVjLPFQyTnWwY4Tpc44h[XO\|YYm=	MYewMlEuOzBizszN	Mn7hNlQhcA>?	MlPPSI94dnKnZ4XsZZRqd25ib3[gd5Vzfmm4aX6g[ZhxemW\|c3nvckBqdiCqdX3hckBNVkODUDDj[YxteyCjdDCwMlEhfG9iM{CgeW0h[W[2ZYKgNlQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	M13hcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEOyN\|E3Lz5{MkizNlMyPjxxYU6=
human LNCAP cells	M2DiTWZ2dmO2aX;uJIF{e2G7	MlnxNE4yNTNyIN88US=>	NHP2WGw{OCCvaX6=	MmTxTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFzOR2FRKGOnbHzzJIF1KDBwMTD0c{A{OCC3TTDh[pRmeiB\|MDDtbY5{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	NWmwTGR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4N\|I{OTZpPkKyPFMzOzF4PD;hQi=>
human PC3 cells	NYm3V3NOTnWwY4Tpc44h[XO\|YYm=	Ml\yOVAh\|ryP	MofYPEBp	NG\tVm1KdmS3Y4Tpc44hd2ZicEKxJJBzd3SnaX6g[ZhxemW\|c3nvckBqdiCqdX3hckBRSzNiY3XscJMh[XRiNUCgeW0hcW6ldXLheIVlKG[xcjC4JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIILlcIF1cX[nIITvJJVvfHKnYYTl[EBkd262cn;s	MlnKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7OUi0O\|IoRjJ{OUm4OFczRC:jPh?=
human BT474 cell	MlLvVJJwdGmoZYLheIlwdiCjc4PhfS=>		M33Rb\|czKGh?	MknoTY5pcWKrdHnvckBw\iCqdX3hckBDXDR5NDDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IIPw[YN1em:yaH;0c41mfHKrYzDhcoFtgXOrc,-8kEBKSzVyPUKwMlch\|ryPLh?=	MkTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUCwNFUoRjJ\|NEGwNFA2RC:jPh?=
human PC3 cell	MkTlVJJwdGmoZYLheIlwdiCjc4PhfS=>		MmKzO\|IhcA>?	MlTOTY5pcWKrdHnvckBw\iCqdX3hckBRSzNiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSC\|cHXjeJJweGixdH;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:OTJwMTFOwG0v	NIryVWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxNFAxPSd-MkO0NVAxODV:L3G+
human PC3 cells	MnzZSpVv[3Srb36gZZN{[Xl?		M2fV[\|MxKG2rbh?=	MlPkTY5pcWKrdHnvckBw\iCSSUPLJIlvKGi3bXHuJHBEOyClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDBT3QheGixc4Doc5J6dGG2aX;uJIF1KHOncnnu[UA1PzNiYX\0[ZIhOzBibXnud{BjgSCHTFnTRUwhUUN3ME2xMlPPxE1w	MljNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUCwNFUoRjJ\|NEGwNFA2RC:jPh?=
human MGC803 cells	MU\GeY5kfGmxbjDhd5NigQ>?	NEPFTYczPSEQvF2=	MXS0PEBp	MoXzR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gUWdEQDB\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCJMj;NJJBp[XOnIHH0JFI2KHWPIHHmeIVzKDR6IHjyd{B2e2mwZzDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHHmeIVzKDR6IHjyd{BjgSCobH;3JIN6fG:vZYTldkBz\WyjdHn2[UB1dyClb370do9t	M1;2NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUG5PFY6Lz5{NEGxPVg3QTxxYU6=
mouse RAW264.7 cells	NGXIXoFHfW6ldHnvckBie3OjeR?=	M1K4dFI2KM7:TR?=	MWmyNEBp	Mm\OTY5pcWKrdHnvckBw\iCSSUPLM2FMXCCrbjDtc5V{\SCUQWeyOlQvPyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGxRWy2rbnT1Z4VlKGmQT2OgdJJwfGWrbjDlfJBz\XO\|aX;uJIF1KDJ3IN88UUBi\nSncjCyNEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	NUfLTVQ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVk3OTZpPkK0Nlk6PjF4PD;hQi=>
human A549 cells	M{PHTnBzd2yrZnXyZZRqd25iYYPzZZk>		MWO3NkBp	M2fCbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD16Mj6zNkDPxE1w	NHS5fW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[5N\|c5Pyd-MkW2PVM4QDd:L3G+
human HuH7 cells	MXrQdo9tcW[ncnH0bY9vKGG\|c3H5		NWXpTVg5PzJiaB?=	Mlv4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKdVi3JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXLzc5Jj[W6lZTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTZ5LkG4JO69VS5?	NIfNTFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[5N\|c5Pyd-MkW2PVM4QDd:L3G+
human HCT116 cells	M4nIOXBzd2yrZnXyZZRqd25iYYPzZZk>		Mn;OO\|IhcA>?	MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD13MT64NkDPxE1w	NGXCU489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[5N\|c5Pyd-MkW2PVM4QDd:L3G+
human HL60 cells	M2T4OnBzd2yrZnXyZZRqd25iYYPzZZk>		M32xUVczKGh?	MnLtRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKTE[wJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXLzc5Jj[W6lZTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTF6LkSzJO69VS5?	MmraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OUO3PFcoRjJ3NkmzO\|g4RC:jPh?=
Sf9 cells	MkC0SpVv[3Srb36gZZN{[Xl?			NICyZnBKdmirYnn0bY9vKG:oIFjpd{11[WepZXSgbJVu[W5iQ1uyJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNuIFnDOVAhRSB4Lkmg{txONg>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODl7OEO1NUc,OTB7OUizOVE9N2F-
HeLa cells	M3\wZ2Z2dmO2aX;uJIF{e2G7			NHX6[WlKdiC4aYTyc{BqdmirYnn0bY9vKG:oIFTORU1l\XCnbnTlcpQheHKxdHXpckBscW6jc3WoSG5CNVCNKTDmdo9uKEinTHGgLIh2dWGwIHPhdoNqdm:vYTmgZ4VtdHNwLDDJR\|UxKD1iMT60JO69VS5?	M{LGOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{OUSxN\|M6Lz5zMkm0NVM{QTxxYU6=
HeLa cells	NGHhUJBHfW6ldHnvckBie3OjeR?=			NGrUXlVKdmirYnn0bY9vKG:oIFTORUBl\XCnbnTlcpQheHKxdHXpckBscW6jc3WgbZNwdGG2ZXSg[pJwdSCKZVzhJINmdGy\|LDDJR\|UxKD1iMT61JO69VS5?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTZ3OEi3NEc,OTV4NUi4O\|A9N2F-
Sf21 cells	MmriSpVv[3Srb36gZZN{[Xl?			MYXJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1vi[ZRiKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{1qdm[nY4Tl[EBU\jJzIHPlcIx{NCCLQ{WwJF0hOC57IN88UU4>	NWjDTIVpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFgzPjlpPkG5O\|Q5OjZ7PD;hQi=>
Sf21 cells	NYHJV2NFTnWwY4Tpc44h[XO\|YYm=			MojRTY5pcWKrdHnvckBw\iCkb4\pcoUhemWlb33ibY5idnRiUFmzT4didW2jIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2ey2rbn\lZ5Rm\CCVZkKxJINmdGy\|LDDJR\|UxKD1iNzFOwG0v	NV2yRmJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFgzPjlpPkG5O\|Q5OjZ7PD;hQi=>
HeLa cells	NIX5V3FHfW6ldHnvckBie3OjeR?=			NELSU2VC[3Srdnn0fUBifCCSSUPLJIlvKGi3bXHuJGhmVGFiY3XscJMh[nliRVzJV2EtKEWFNUCgQUAyNjVizszNMi=>	Mm\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOUKzNlMoRjJyMEmyN\|I{RC:jPh?=
Sf21 cells	NIHxZo9HfW6ldHnvckBie3OjeR?=			MXnJcohq[mm2aX;uJI9nKFCLM1vk[Yx1[SCneIDy[ZN{\WRiaX6gZ4VtdHNiY3:t[ZhxemW\|c3nu[{BPNXSncn3pcoFtKEircz30ZYdo\WRiaIXtZY4heDh3YTD1d4lv\yCOLXHsdIhiNXCqb4PwbIF1cWS7bHnuc5NqfG:uIIP1ZpN1emG2ZTDifUBVVENiYnHz[YQheGixc4Doc5IhcW2jZ3nu[{whUUN3MDC9JFAvPTdizszNMi=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV{ME[zNEc,OjJ3MkC2N\|A9N2F-
Sf21 cells	NInDNm1HfW6ldHnvckBie3OjeR?=			Mly5TY5pcWKrdHnvckBw\iCqdX3hckB4cWymIIT5dIUhWEl\|S3LleIEh\XiycnXzd4VlKGmwIGPmNlEh[2WubIOgZ48u\XiycnXzd4lv\yCQLYTldo1qdmGuIFjpd{11[WepZXSgbJVu[W5icEi1ZUB2e2mwZzDMMYFteGijLYDoc5NxcGG2aXT5cIlvd3OrdH;sJJN2[nO2cnH0[UBjgSCWTFOgZoF{\WRicHjvd5Bpd3JiaX3h[4lv\yxiSVO1NEA:KDBwOUeg{txONg>?	NYHLO3VTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1NlA3OzBpPkKyOVIxPjNyPD;hQi=>
HL60 cells	M4HubWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1Tk[\|Mh\GG7cx?=	MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOyCmYYnzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDF2IN88UU4>	NUHve49VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OFUyOTBpPkK2PVQ2OTFyPD;hQi=>
U937 cells	NXv5XFZmSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MUCzJIRigXN?	M3nPbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUmzO{Bk\WyuczDt[YF{fXKnZDDh[pRmeiB\|IHThfZMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iMUSg{txONg>?	NU\LRVJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OFUyOTBpPkK2PVQ2OTFyPD;hQi=>
Jurkat cells	MUTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NVGwSXBROyCmYYnz	MlOyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCMdYLrZZQh[2WubIOgcYVie3W{ZXSgZYZ1\XJiMzDkZZl{KGK7IF3UV{Bie3OjeTygTWM2OCB;IEKyJO69VS5?	NU\rNXdsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OFUyOTBpPkK2PVQ2OTFyPD;hQi=>
K562 cells	M1\QR2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NUjt[XBzOyCmYYnz	NVfPRnFSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJI1m[XO3cnXkJIFnfGW{IEOg[IF6eyCkeTDNWHMh[XO\|YYmsJGlEPTBiPTCzPEDPxE1w	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl2NUGxNEc,OjZ7NEWxNVA9N2F-
U266 cells	NH3NSGNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NX;PSIRiOyCmYYnz	MojJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCXMk[2JINmdGy\|IH3lZZN2emWmIHHmeIVzKDNiZHH5d{BjgSCPVGOgZZN{[XluIFnDOVAhRSB2NjFOwG0v	NIDFb\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm0OVEyOCd-Mk[5OFUyOTB:L3G+
MDA-MB-231 cells	M{TqSmFvfGmvaXfyZZRwenliYYPzZZk>		MWGyOEBpenN?	MX7BcpRqdWmpcnH0c5J6KGGldHn2bZR6KGGpYXnud5QhTUeIIHnu[JVk\WRiY3jlcY91[XirczDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IIDy[Ylv[3WkYYTl[EBnd3JiMkSgbJJ{KG[xbHzve4VlKGK7IFXHSkBi\GSrdHnvckBnd3JiMz61JIhzeyCkeTDsbYdpfCCvaXPyc5Nkd3C7LDDJR\|UxKD1iMD6zPEDPxE1w	NIjVc4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W5PFI{Pyd-Mke1PVgzOzd:L3G+
MDA-MB-231 cells	MoewRY51cWmwdnHzbZZmKGG\|c3H5		MlXYN{42KGi{cx?=	NX;DOZk6SW62aXnueoF{cX[nIHHjeIl3cXS7IHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCHR1[tbY5lfWOnZDDj[YxtKGmwdnHzbY9vKGGodHXyJFMvPSCqcoOsJGlEPTBiPTCwMlM5KM7:TT6=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDByOUWyNUc,OjhyMEm1NlE9N2F-
HEK293T cells	NIT1N4xHfW6ldHnvckBie3OjeR?=		NVfEWog{OSCqch?=	MVvJcohq[mm2aX;uJI9nKGmvbX;ibYxqgmWmIF6tUHkzQTRyMEKgZoVi\CCkaX7kbY5oKHSxIGDJN2tj\XSjIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGhGUzJ7M2SgZ4VtdHNiaX7jeYJifGWmIH\vdkAyKGi{IHL5JGxENU2VL13TJIFv[Wy7c3nzMEBKSzVyIE2gNE41OiEQvF2u	MoTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OECyOlEoRjJ6MkiwNlYyRC:jPh?=
HEK293T cells	M{DyNmZ2dmO2aX;uJIF{e2G7		M2KwfFEhcHJ?	MUjJcohq[mm2aX;uJI9nKGmvbX;ibYxqgmWmIF6tUHkzQTRyMEKgZoVi\CCkaX7kbY5oKHSxIGDJN2tl\Wy2YTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBJTUt{OUPUJINmdGy\|IHnuZ5Vj[XSnZDDmc5IhOSCqcjDifUBNSy2PUz;NV{BidmGueYPpd{whUUN3MDC9JFEvPTNizszNMi=>	NUXiTm16RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFAzPjFpPkK4NlgxOjZzPD;hQi=>
HEK293T cells	NX3Kc\|hJTnWwY4Tpc44h[XO\|YYm=		M33S[VEhcHJ?	MYTJcohq[mm2aX;uJI9nKGmvbX;ibYxqgmWmIF6tUHkzQTRyMEKgZoVi\CCkaX7kbY5oKHSxIGDJN2tidHCqYTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBJTUt{OUPUJINmdGy\|IHnuZ5Vj[XSnZDDmc5IhOSCqcjDifUBNSy2PUz;NV{BidmGueYPpd{whUUN3MDC9JFIvOzdizszNMi=>	M{PnXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiwNlYyLz5{OEK4NFI3OTxxYU6=
MDA-MB-231 cells	NF:wWYtHfW6ldHnvckBie3OjeR?=			MojlTY5pcWKrdHnvckBw\iCHR1[tbY5lfWOnZDDpcpZie2mxbjDv[kBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOzhizszNMi=>	MmLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MEK0NFEoRjJ6M{CyOFAyRC:jPh?=
MCF7 cells	NYPMdJNQTnWwY4Tpc44h[XO\|YYm=	MnTiNVAhfU1?	Mn;YNUBpeg>?	MYjJcohq[mm2aX;uJI9nKEmJRkHSJJBpd3OyaH;yfYxifGmxbjDheEBVgXJzMU[xJJJme2mmdXWgbY4hcHWvYX6gUWNHPyClZXzsd{BifCBzMDD1UUBi\nSncjCxJIhzKGK7IFjv[YNpe3RiM{OyOVghe3SjaX7pcoch[mG\|ZXSgbY1ufW6xaHnzeI9kcGWvaXPhcEBidmGueYPpdy=>	NYrmZ3NTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1OzBpPkK4OVU4PDNyPD;hQi=>
SKOV3 cells	MXLGeY5kfGmxbjDhd5NigQ>?	NEnU[JMzOCC3TR?=	Mkf4NlQhcHK\|	MWfJcohq[mm2aX;uJI9nKEKGTl[tbY5lfWOnZDDpcpZie2mxbjDpckBpfW2jbjDTT29XOyClZXzsd{BifCB{MDD1UUBi\nSncjCyOEBpenNiaX6gZpkhdWG2cnnn[YwhcW64YYPpc44h[XO\|YYm=	M3ftblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUKyOFg1Lz5{OUGyNlQ5PDxxYU6=
SKOV3 cells	MnPkRY51cW2rZ4LheI9zgSCjc4PhfS=>	NGn0dHkzOCC3TR?=	Mm[3NlQhcHK\|	NYnTT\|lOSW62aX3p[5JifG:{eTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONT2[zJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiQlTOSk1qdmS3Y3XkJINmdGxibXnndoF1cW:wIHH0JFIxKHWPIHHmeIVzKDJ2IHjyd{BjgSC\|Y4LheINpKHexdX7kJIhm[WyrbnegZZN{[Xl?	NELGc3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUGyNlQ5PCd-MkmxNlI1QDR:L3G+
NB1643 cells	M3m2cJFJXFNiYYPzZZk>			NGfD[JJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	MlLQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 cells	MljpdWhVWyCjc4PhfS=>			MWrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	NUHWb4VKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 cells	NHrscVlyUFSVIHHzd4F6			NF\MdpdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	NFXOfZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC cells	NIr5TXRyUFSVIHHzd4F6			M2rXdZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	MnHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
J774 cells	MXLBcpRqcW6obHHtcYF1d3K7IHHzd4F6		M2XTO\|I1KGi{cx?=	NEDrPYJCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJGo4PzRiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGxRWy2rbnT1Z4VlKE2FUEGg[ZhxemW\|c3nvckBi\nSncjCyOEBpenNiYomgSWxKW0FuIFnDOVAhRSB\|Lkeg{txONg>?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd{Nk[4NEc,Ojl5Mk[2PFA9N2F-
J774 cells	NYfxWFVqSW62aXnu[oxidW2jdH;yfUBie3OjeR?=		NX3RO2RsOjRiaILz	M2PscGFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgTlc4PCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gUHBUNWmwZIXj[YQhUUx4IHX4dJJme3Orb36gZYZ1\XJiMkSgbJJ{KGK7IFXMTXNCNCCLQ{WwJF0hPS5zIN88UU4>	NUmxPHVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3NlY3QDBpPkK5O\|I3PjhyPD;hQi=>
J774 cells	NXu4UY9SSW62aXnu[oxidW2jdH;yfUBie3OjeR?=		MYKyOEBpenN?	NYPpSGFzSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBLPzd2IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBNWFNvaX7keYNm\CCwaYTybYMhd3irZHWgdJJw\HWldHnvckBi\nSncjCyOEBpenNiYomgS5Jq\XO\|IHHzd4F6NCCLQ{WwJF0hQC57IN88UU4>	NVfSPW5RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3NlY3QDBpPkK5O\|I3PjhyPD;hQi=>
J774 cells	MoW5SpVv[3Srb36gZZN{[Xl?	NGnCV5gyOCC3TR?=	NX7lUmNyPCCqcoO=	Mn\1TY5pcWKrdHnvckBw\iCSSUPLM2FsfCCrbjDtc5V{\SCMN{e0JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCOUGOtbY5lfWOnZDDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFOnckS3N{BifCBzMDD1UUBi\nSncjC0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd{Nk[4NEc,Ojl5Mk[2PFA9N2F-

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	E-cadherin / p-Akt / Akt ; beta-catenin / p-GSK3β / Cyclin D1 ; Bcl-xl / Bax / caspase3 / cleaved caspase-3 ; p-p70S6K (T389) / p-GSK3β(S9) / pERK / Vinculin ; pPKB-S473	29731993 25344912 23251002 20649566
Growth inhibition assay	Cell viability	25344912
Immunofluorescence	α-SMA / CD31 ; E-cadherin / beta-catenin ; COX-2 / p-NFκB ; FOXO3a	27671604 29731993 18388194
ELISA	IL-10 / IL-1β / TNFα / IL-6	22208359

In vivo

LY294002 also results in suppression of tumor growth and induction of apoptosis, especially in the LoVo tumors, and therefore shows remarkable effectiveness in the mouse peritonitis carcinomatosa model. ^[2] LY294002 significantly inhibits growth and ascites formation of ovarian carcinoma. ^[3]

Protocol (from reference)

Kinase Assay: ^[4]	kinase assays: PI3K inhibition by LY294002 is determined in a radiometric assay using purified, recombinant enzymes with 1 μM ATP. The kinase reaction is carried out for 1 hour at room temperature (24^oC) and is terminated by addition of PBS. IC50 values are subsequently determined using a sigmoidal dose–response curve fit (variable slope). CK2 and GSK3β (glycogen synthase kinase 3β) inhibition is established by kinase selectivity screening. LY294002 is tested against the Upstate panel of kinases in 10 μM ATP.
Cell Research: ^[2]	Cell lines: Colon cancer cell lines DLD-1, LoVo, HCT15, and Colo205 Concentrations: 0–50 μM Incubation Time: 0–48 hours Method: 1.0×10⁵ cells (100 μL volume/well) are inoculated into 96-well microtiter plates. LY294002 is added to triplicate wells and cultured at 37^oC for 0–48 hours. After treatment, 10 μL of Premix WST-1 are added to each microculture well, and the plates are incubated for 60 minutes at 37^oC, after which absorbance at 450 nm is measured with a microplate reader. (Only for Reference)
Animal Research: ^[3]	Animal Models: Two groups of athymic nude mice (5–7 weeks) are inoculated i.p. with OVCAR-3 cells Dosages: 0–100 mg/kg Administration: Administered via i.p. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	36 mg/mL warmed (117.13 mM)
	Water	Insoluble
	Ethanol	'21 mg/mL
In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 5% DMSO+ 40%PEG 300+5% Tween 80+50%ddH2O For best results, use promptly after mixing. Click to purchase: PEG300 Tween 80	3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	307.34
Formula	C₁₉H₁₇NO₃
CAS No.	154447-36-6
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4

Download LY294002 SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02337309	Terminated	Drug: SF1126	Neuroblastoma	New Approaches to Neuroblastoma Therapy Consortium\|SignalRX Pharmaceuticals Inc.\|University of Southern California	July 9 2015	Phase 1

(data from https://clinicaltrials.gov, updated on 2021-09-06)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
I want to buy a inhibitor that can inactivates Akt/PI3K. I notice the protocol of LY294002 (catalog no. s1105) says it will inactivates Akt/PKB. Is LY294002 available for Akt/PI3K inhibition?

Answer:
LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively. It can inhibit PI3K/AKT. PKB is the alternative name of AKT.

Question 2:
What is the suggested formulation of this compound for mouse injection(i.p.)?

Answer:
It can be dissolved in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O at 5 mg/ml clearly, and the concentration of DMSO is safe for in vivo experiments.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):